» Articles » PMID: 39337488

How Protein Depletion Balances Thrombosis and Bleeding Risk in the Context of Platelet's Activatory and Negative Signaling

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Sep 28
PMID 39337488
Authors
Affiliations
Soon will be listed here.
Abstract

Platelets are small cell fragments that play a crucial role in hemostasis, requiring fast response times and fine signaling pathway regulation. For this regulation, platelets require a balance between two pathway types: the activatory and negative signaling pathways. Activatory signaling mediators are positive responses that enhance stimuli initiated by a receptor in the platelet membrane. Negative signaling regulates and controls the responses downstream of the same receptors to roll back or even avoid spontaneous thrombotic events. Several blood-related pathologies can be observed when these processes are unregulated, such as massive bleeding in activatory signaling inhibition or thrombotic events for negative signaling inhibition. The study of each protein and metabolite in isolation does not help to understand the role of the protein or how it can be contrasted; however, understanding the balance between active and negative signaling could help develop effective therapies to prevent thrombotic events and bleeding disorders.

References
1.
Burla B, Oh J, Nowak A, Piraud N, Meyer E, Mei D . Plasma and platelet lipidome changes in Fabry disease. Clin Chim Acta. 2024; 562:119833. DOI: 10.1016/j.cca.2024.119833. View

2.
Soares Ferreira Junior A, Lessa M, Sanborn K, Gordee A, Kuchibhatla M, Karafin M . Bleeding recurrence risk among hospitalized patients undergoing therapeutic plasma exchange: a multi-center study. Blood Transfus. 2024; 22(5):420-428. PMC: 11390607. DOI: 10.2450/BloodTransfus.722. View

3.
Mani S, Jindal D, Chopra H, Jha S, Singh S, Ashraf G . ROCK2 inhibition: A futuristic approach for the management of Alzheimer's disease. Neurosci Biobehav Rev. 2022; 142:104871. DOI: 10.1016/j.neubiorev.2022.104871. View

4.
Ahmad K, Lee E, Shaikh S, Kumar A, Rao K, Park S . Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges. Semin Cancer Biol. 2019; 69:325-336. DOI: 10.1016/j.semcancer.2019.08.030. View

5.
Wang L, Wu Y, Zhou J, Ahmad S, Mutus B, Garbi N . Platelet-derived ERp57 mediates platelet incorporation into a growing thrombus by regulation of the αIIbβ3 integrin. Blood. 2013; 122(22):3642-50. PMC: 3837513. DOI: 10.1182/blood-2013-06-506691. View